BEDFORD, Mass. - Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company specializing in eye therapies, has appointed Steve Meyers as its new Chief Commercial Officer, the company announced today. Meyers, who brings over two decades of commercial experience in the biotechnology sector, steps into his new role after serving as Vice President of Sales at Flexion Therapeutics (NASDAQ:FLXN).
Antony Mattessich, CEO of Ocular Therapeutix, expressed confidence in Meyers' ability to drive the company's commercial strategies due to his proven leadership and comprehensive understanding of the company's mission. Meyers himself commented on his commitment to advancing the company's drug portfolio to improve patient quality of life and deliver value to shareholders.
Meyers' background includes product launches in competitive markets and roles at established biotech firms such as Regeneron (NASDAQ:REGN) and AbbVie (NYSE:ABBV). He holds a B.S. from Louisiana State University in Cardiopulmonary Science.
Ocular Therapeutix focuses on developing treatments for eye diseases using its proprietary hydrogel-based technology, ELUTYX™. Its FDA-approved product, DEXTENZA®, addresses ocular inflammation and pain post-surgery, and allergic conjunctivitis. The company also has several products in development, including AXPAXLI for wet age-related macular degeneration (AMD (NASDAQ:AMD)) and PAXTRAVA™ for glaucoma, both undergoing clinical trials.
The company's forward-looking statements indicate ongoing efforts to commercialize DEXTENZA and the progression of its clinical trials for other potential therapies. However, these statements are subject to various risks and uncertainties, and the future performance and achievements of Ocular Therapeutix may differ from current projections.
This news is based on a press release statement from Ocular Therapeutix, Inc. and does not necessarily reflect future results or events which are inherently uncertain.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.